Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children.

Avner ReshefVesna Grivcheva-PanovskaAharon KesselShmuel KivityMaria Klimaszewska-RembiaszDumitru MoldovanHenriette FarkasVaclava GutovaStephen FritzAnurag RelanBruno GiannettiMarkus Magerl

Published in: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2019)

Recombinant human C1-INH was efficacious, safe, and well tolerated in children. Data support use of the same dosing regimen for HAE attacks in children (50 IU/kg; up to 4200 IU, followed by an additional dose, if needed) as is currently recommended for adolescents and adults.

Keyphrases

recombinant human
young adults
physical activity
electronic health record
big data
combination therapy
smoking cessation